Responses
Clinical/translational cancer immunotherapy
Original research
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Compose a Response to This Article
Other responses
No responses have been published for this article.